The re-rating case — EV ₹12,038 Cr − net debt ₹8,622 Cr = market cap ₹3,416 Cr (0.22× sales, 0.42× book). Cycle recovery + deleverage + Asepto/value-added mix are the levers; the leverage trend is shown honestly.
Enterprise value has gone from ₹9.54k Cr (FY25) to ₹12.10k Cr today — but the equity is just ₹3.42k Cr, because ₹8.62k Cr of net debt (4.35× EBITDA, up from 3.73×) stands in front of it: the market prices the leverage and the films cycle at 0.22× sales / 0.42× book. The re-rating case is cycle recovery + deleverage + Asepto/value-added mix toward 40% — ₹9.50k Cr of EV remains to the ₹21.60k Cr FY28 target, and most of every rupee gained lands on the equity.
4 of 4 headline metrics improving vs prior · still off target: Revenue from Operations ₹15,401 Cr vs ₹16,500 Cr, EBITDA (Reported) ₹1,984 Cr vs ₹2,400 Cr, EBITDA Margin (Reported) 12.8% vs 15.0%
₹9.50k Cr of enterprise value stands between today's ₹12.10k Cr and the ₹21.60k Cr FY28 target — and with ₹8.62k Cr of net debt fixed ahead of a ₹3.42k Cr equity, EV gains land on shareholders roughly 3.5× levered.
₹335 Cr of ₹430 Cr run-rate program EBITDA is still to capture — the same work that lands the Egypt commissioning, the recycling ramp and the margin path from 12.8% toward 15% (Q4 exited at 15.3%).
Mix shift, Asepto scale-up, recycling / Project Plastic Fix, chips integration, working capital & MES
Climbing to the value-added-packaging tier is worth 2–3 EBITDA turns — on ₹1.98k Cr of EBITDA that is ₹3.97k Cr–₹5.95k Cr of EV from re-rating alone, nearly all of it equity.
UFlex runs a Value Creation Plan from FY25 to the FY28 target. On ₹15.40k Cr of revenue the market pays just ₹3.42k Cr of equity — it prices the 4.35× leverage (risen from 3.73× through the ₹2,044 Cr capex cycle) and the commodity-films cyclicality, not the topline. The prize is deleverage + multiple re-rating: less-cyclical Asepto, holography & specialty converting revenue is valued at a premium, and every EBITDA turn gained lands ~3.5× on the equity. This is the screen that tracks it.
Each lever shown start → today → target, with progress through the plan.
| Workstream | Lever | Start | Today | Target | Progress | Status |
|---|---|---|---|---|---|---|
| Scale the platform | Volume-led growth on commissioned assets (FY27+) | ₹15,036 Cr | ₹15,401 Cr | ₹18,000 Cr | On track | |
| Shift to value-added | Laminates, Asepto, holography, specialty & PCR films | 28.6% | 33% | 40% | On track | |
| Expand margin | Mix + films-cycle recovery + chips integration | 12.1% | 12.8% | 15% | Behind | |
| Grow profit | Scale × margin | ₹1,834 Cr | ₹1,984 Cr | ₹2,700 Cr | On track | |
| Deleverage the balance sheet | OCF sweep + capex moderation after the build | 3.73× | 4.35× | 3× | Behind | |
| Re-rate the multiple | Deleverage + Asepto + margin proof (vs 0.22× sales today) | 5.2× | 6.1× | 8× | On track |
Value-added & converting mix moves the EBITDA multiple. At 33%, UFlex sits in the integrated films-to-packaging platform tier — every point toward 40% pulls it up. (EPL, at 20% OPM, trades at 2× UFlex's mcap on ⅓ the revenue.)
Climbing to the value-added-packaging tier is worth 2–3 EBITDA turns — on ₹1.98k Cr of EBITDA, that's ₹3.97k Cr–₹5.95k Cr of enterprise value from re-rating alone; with the debt stack fixed, nearly all of it accrues to the equity.
Less-cyclical aseptic packs (7.97 bn sold FY26), holography & security programs and specialty/PCR films (Asclepius, F-TPM, F-WSP) command a richer EV/revenue than commodity films — separate from, and on top of, the blended multiple.
So what: scaling Asepto (12→24 bn packs with Egypt), holography and specialty/PCR converting creates value at a premium multiple — well above the 6.1× the blended cyclical trades at. With ₹8,622 Cr of net debt ahead of ₹3,416 Cr of equity, it's the single highest-torque rupee in the plan.
The concrete programs behind the realization % — not a slogan, a checklist.
UFlex's program playbook in action: value-added & specialty mix shift (Alox / high-barrier / PCR), aseptic scale-up & Egypt commissioning, recycling / Project Plastic Fix on the EPR tailwind, chips backward integration (Panipat & Egypt), working-capital & deleverage, and plant MES across 9 countries. ₹335 Cr of run-rate is still to capture — the same work behind the margin path (12.8%→15%; Q4 exited at 15.3%) and the FY27 deleverage.